CompletedPHASE2, PHASE3NCT01110720
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Studying Classic progressive supranuclear palsy syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Allon Therapeutics
- Principal Investigator
- Adam Boxer, M.D., PhD.Memory and Aging Center, University of California, San Francisco
- Intervention
- Davunetide(drug)
- Enrollment
- 313 enrolled
- Eligibility
- 41-85 years · All sexes
- Timeline
- 2010 – 2012
Study locations (30)
- University of Alabama - Birmingham, Birmingham, Alabama, United States
- Muhammed Ali Parkinson Center and Movement Disorders Clinic, Phoenix, Arizona, United States
- Mayo Clinic, AZ, Scottsdale, Arizona, United States
- USC Keck School of Medicine, Los Angeles, California, United States
- David Geffen School of Medicine - UCLA, Los Angeles, California, United States
- UCSD/VA Neurology Service, San Diego, California, United States
- UCSF Memory and Aging Center, San Francisco, California, United States
- Colorado Neurological Institute - Rocky Mountain Movement Disorders Ctr, PC, Englewood, Colorado, United States
- Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
- Mayo Clinic, Florida, Jacksonville, Florida, United States
- The Frances J. Zesiewicz Foundation for Parkinson's Disease at USF, Tampa, Florida, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- University of Kansas Medical Center Parkinson Disease & Movement Disorders Center, Kansas City, Kansas, United States
- University of Louisville Division of Movement Disorders, Louisville, Kentucky, United States
- John Hopkins Hospital, Baltimore, Maryland, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01110720 on ClinicalTrials.govOther trials for Classic progressive supranuclear palsy syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07509125Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic DisordersUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGEARLY PHASE1NCT07348276First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the BrainInvicro
- RECRUITINGNANCT07291687tDCS as Treatment for Motor FunctionBaycrest
- ACTIVE NOT RECRUITINGNANCT06588673Art Therapy in Progressive Supranuclear PalsyVanderbilt University Medical Center
- ENROLLING BY INVITATIONNANCT06597071Parkinson Atypical Rating of Oculometric Patterns Evaluated RoutinelyNeuraLight
- ACTIVE NOT RECRUITINGPHASE2NCT06355531A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)Ferrer Internacional S.A.
- RECRUITINGNCT06949865AI-Enhanced Optimization of Acute Levodopa Challenge TestBeijing Tiantan Hospital
- RECRUITINGNANCT06174948The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related DisordersQueen Mary University of London
See all trials for Classic progressive supranuclear palsy syndrome →